July 16, 2026- Abbott announced financial results for the second quarter ended June 30, 2026.
- Second-quarter sales increased 13.0 percent on a reported basis and 4.8 percent on a comparable basis.
- Second-quarter GAAP diluted EPS of $0.53 and adjusted diluted EPS of $1.31, which excludes specified items.
- Abbott reaffirms full-year 2026 comparable sales growth guidance of 6.5% to 7.5%1.
- Abbott raises full-year 2026 adjusted diluted EPS guidance range to $5.45 to $5.60, compared to previous range of $5.38 to $5.58.
- In April, Abbott completed enrollment in its TECTONIC U.S. pivotal trial. This trial is designed to evaluate Abbott’s investigational Coronary Intravascular Lithotripsy (IVL) System for treating severe calcification in coronary arteries prior to stent implantation.
- In April, at the Heart Rhythm Society (HRS) conference, Abbott presented new late-breaking data from four clinical trials that demonstrated strong clinical outcomes across the company’s pulsed field ablation (PFA) and conduction system pacing (CSP) portfolios.